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130Objective: SYNTAX study compares outcomes of coronary artery bypass grafting with percutaneous coronary
intervention in patients with 3-vessel and/or left main disease. Complexity of coronary artery disease was quan-
tified by the SYNTAX score, which combines anatomic characteristics of each significant lesion. This study
aims to clarify whether SYNTAX score affects the outcome of bypass grafting as defined by major adverse ce-
rebrovascular and cardiac events (MACCE) and its components over a 2-year follow-up period.
Methods:Of the 3075 patients enrolled in SYNTAX, 1541 underwent coronary artery bypass grafting (897 ran-
domized controlled trial patients, and 644 registry patients). All patients undergoing bypass grafting were strat-
ified according to their SYNTAX score into 3 tertiles: low (0–22), intermediate (22–32), and high (33)
complexity. Clinical outcomes up to 2 years after allocation were determined for each group and further risk
factor analysis was performed.
Results: Registry patients had more complex disease than those in the randomized controlled trial (SYNTAX
score: registry 37.8 13.3 vs randomized 29.1 11.4; P<.001). At 30 days, overall coronary bypass mortality
was 0.9% (registry 0.6% vs randomized 1.2%). MACCE rate at 30 days was 4.4% (registry 3.4% vs random-
ized 5.2%).
SYNTAX score did not significantly affect overall 2-year MACCE rate of 15.6% for low, 14.3% for medium,
and 15.4% for high SYNTAX scores. Compared with randomized patients, registry patients had a lower rate of
overall MACCE rate (registry 13.0% vs randomized 16.7%; P ¼ .046) and repeat revascularization (4.7% vs
8.6%; P ¼ .003), whereas other event rates were comparable. Risk factor analysis revealed left main disease
(P ¼ .049) and incomplete revascularization (P ¼ .005) as predictive for adverse 2-year outcomes.
Conclusions: The outcome of coronary artery bypass grafting was excellent and independent from the SYN-
TAX score. Incomplete revascularization rather than degree of coronary complexity adversely affects late out-
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The Journal of Thoracic and Cardiovascular SurgCoronary artery bypass grafting (CABG) rather than percu-
taneous coronary intervention (PCI) is recommended to be
the primary revascularization strategy for patients with sta-
ble angina who have coronary triple vessel disease (3-VD)
or left main (LM) disease.1-4 This recommendation is based
on results of several randomized controlled trials, meta-
analyses and registry data comparing CABG surgery with
bare metal stent as well as contemporary PCI technolo-
gies.5-8 Increasing use of drug-eluting stents and greater op-
erator experience has resulted in PCI being performed in
patients with increasingly complex coronary pathologic
conditions and class I surgical indications.9 Studies compar-
ing PCI with drug-eluting stents to CABG for prognostic in-
dications have generally been limited to nonrandomized
studies thus far and have demonstrated significant advan-
tages of CABG over PCI for repeat revascularization. How-
ever, such studies have failed to demonstrate survival
benefit for CABG, probably because of inadequately pow-
ered study designs.10-12 Nevertheless, surgeons areery c January 2011
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CVA ¼ cerebrovascular accident
ITA ¼ internal thoracic artery
LAD ¼ left anterior descending coronary
artery
LM ¼ left main
MACCE ¼ major adverse cardiac and
cerebrovascular event
MI ¼ myocardial infarction
OUS ¼ outside the United States
PCI ¼ percutaneous coronary intervention
SYNTAX ¼ SYNergy between PCI with TAXUS
and Cardiac Surgery
US ¼ United States
VD ¼ vessel disease
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Dconfronted with the widespread use of PCI in these patients
despite conflicting support from evidence-based medicine.
The SYNTAX (SYNergy between PCI with TAXUS and
Cardiac Surgery) trial thus assessed for the first time the op-
timal revascularization strategy in 1800 randomized pa-
tients with de novo 3-VD or LM disease comparing
contemporary bypass surgery and PCI with drug-eluting
stents by using a noninferiority study design.13 Patients in-
eligible for PCI treatment were entered into a parallel,
nested CABG registry, and patients deemed ineligible for
CABG were treated with PCI and data integrated in the
PCI registry.
As recently demonstrated, the primary study end point of
major adverse cardiac and cerebrovascular event rate
(MACCE) at 1 year was significantly lower for CABG
(12.4%) than for PCI (17.8%) patients.14
A secondary objective of the SYNTAX trial was to ana-
lyze the complexity of the coronary artery disease by using
a newly developed SYNTAX score that was derived from
various pre-existing angiographic anatomic classifica-
tions.15 A subgroup analysis of the randomized SYNTAX
study population revealed significant evidence of worse
PCI results in patients with increasingly complex coronary
anatomy.14 This observation was recently confirmed by ret-
rospectively applying the SYNTAX score to other PCI pa-
tient groups, that is, ARTS II and LM disease.16,17 In
contrast, surgical results were less adversely affected by
coronary complexity in the randomized CABG
population. Moreover; there was some evidence of higher
1-year adverse event rates in the low SYNTAX score
group, but this was not observed in the CABG registry at
1 year’s follow-up.14,17,18
The aim of this analysis was to assess the impact of cor-
onary complexity on surgical outcomes up to 2 years post-The Journal of Thoracic and Caoperatively and to identify potential clinical and coronary
risk factors for adverse CABG results by analyzing the en-
tire SYNTAXCABG population (randomized and registry),
which can be considered as representative for contemporary
bypass surgery.METHODS
Study Design and Allocation
BetweenMarch 2005 andMay 2007, a total 85 sites in Europe (17 coun-
tries, 62 sites) and the United States (US, 23 sites) enrolled patients in the
SYNTAX study. The institutional review board at each site approved the
protocol, and all patients provided written informed consent. The protocol
and consent forms were consistent with the Food and Drug Administra-
tion’s Guidance for Industry E6 Good Clinical Practice, the Declaration
of Helsinki, the International Conference on Harmonisation, and all local
regulations, as appropriate.
In contrast to previous comparative studies, patients with significant car-
diac diseases (eg, poor ejection fraction, unstable angina) and severe co-
morbidities (eg, renal dysfunction, carotid artery disease) were not
excluded from SYNTAX, thus allowing the study to better represent real
clinical practice. The SYNTAX ‘‘all-comers’’ study design and patient se-
lection have been previously described in detail.13,14 In brief, patients with
de novo 3-VD and/or LM disease were screened for study suitability by
a local Heart Team that was composed of an interventional cardiologist,
a cardiac surgeon, and the study coordinator. If the consensus decision
was that comparably complete revascularization could be achieved by
either PCI or CABG therapy, the patient was randomized to one of the
treatment options. A total of 903 patients were assigned to PCI using
TAXUS Express paclitaxel-eluting stents (Boston Scientific, Natick,
Mass) and 897 patients were assigned to CABG surgery.13 The primary
study end point for the randomized cohort was the overall MACCE rate
at 12 months’ follow-up, but patients were followed up to 5 years after al-
location. The SYNTAX study also included two nested registries, one for
PCI-ineligible patients (CABG registry) and one for CABG-ineligible pa-
tients (PCI registry). A total of 1079 patients were allocated to the CABG
registry. Reasons not to randomize these patients were predominantly com-
plex coronary anatomy (70.9%) and potentially untreatable coronary
chronic total occlusion (22.0%). Of these patients, 649 were randomly as-
signed to 5-year follow-up, of whom 5 had to be excluded initially because
of no revascularization or medical treatment only. During 2-year follow-up,
12 patients were lost to follow-up or withdrew study consent (follow-up
98.1% complete). From 897 randomized CABG patients, 51 withdrew
study participation and 10 were lost to follow-up, leading to a 2-year
follow-up rate of 93.2% (836 patients). Therefore, a total of 1541 SYN-
TAX CABG patients were assigned to 5 years’ follow-up and analyzed
for the current study (897 randomized and 644 registry patients). Overall
2-year follow-up was available on 1468 CABG patients, corresponding
to a follow-up rate of 95.3%.
Assessment of Coronary Complexity
All preoperative diagnostic angiograms were reviewed by an indepen-
dent core laboratory blinded to treatment assignment (Cardialysis BV, Rot-
terdam, the Netherlands). Diagnostic angiograms were scored according to
the SYNTAX score algorithm. The SYNTAX score is a comprehensive an-
atomic assessment of the coronary disease derived from various pre-
existing anatomic classifications. In brief, each coronary lesion producing
50% luminal obstruction or greater in vessels 1.5 mm or larger is defined
on the basis of the modified American Heart Association coronary tree seg-
ment classification and separately scored regarding segment importance,
bifurcation or trifurcation, aortic ostial localization, chronic total occlu-
sion, vessel tortuosity, lesion length, calcification, and thrombus formation.
Finally, the score of each lesion is added to obtain a patient-specific rawrdiovascular Surgery c Volume 141, Number 1 131
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DSYNTAX score.15 Thus, higher SYNTAX scores are indicative of more
complex coronary disease.16
CABG Surgery
All patients were treated with the intention of complete revasculariza-
tion, defined as bypassing all lesions with 50% or greater stenosis in ves-
sel diameters of more than 1.5 mm as identified by the Heart Team. CABG
technique was performed according to the surgeon’s preference and local
clinical standards. It was recommended to revascularize the left anterior
descending artery (LAD) and the circumflex branches by using either
the left or right internal thoracic artery (ITA), when technically feasible,
and the remaining vessels with either another arterial conduit or a saphe-
nous vein in a configuration deemed appropriate by the surgeon. In pa-
tients less than 70 years of age, complete arterial revascularization was
recommended. It was also left to the surgeon’s preference to operate
with or without cardiopulmonary bypass and, in case of cardioplegic ar-
rest, to use blood or crystalloid cardioplegia. Anesthesia management, in-
cluding the use of aprotinin and postoperative care, was also performed
according to local clinical standards, as was the postoperative medication
regimen. Aspirin was prescribed indefinitely in all randomized CABG pa-
tients only.
End Points
The primary clinical end point was the composite of all MACCEs more
than 12 months after allocation. MACCE was defined as all-cause death,
cerebrovascular accident (CVA), myocardial infarction (MI), and repeat re-
vascularization. CVAwas defined as a focal, central neurologic deficit last-
ing more than 72 hours that resulted in irreversible brain damage or body
impairment. The definition of MI was based on previous studies.10 Safety
end point was a combination from death, CVA, and MI. Repeat revascular-
ization was defined as any postoperative coronary intervention. Complete
revascularization was based on the anatomic (ie, functional) definition by
bypassing all eligible lesions identified during the Heart Team conference.
An independent Clinical Events Committee including cardiologists, car-
diac surgeons, and a neurologist reviewed all primary clinical end points.14
Statistical Analysis
Analyses were conducted using SAS system software, version 8.0 or
higher (SAS Institute, Inc, Cary, NC), and included patients randomized
to CABG (intent-to-treat) or who underwent CABG as part of the
CABG registry and were allocated to 5-year follow-up. Continuous vari-
ables were estimated as mean  standard deviation, and randomized and
registry patients were compared with the Student t test. Discrete variables
were reported as counts and percentages, and differences between ran-
domized and registry patients were assessed by the c2 or Fisher’s exact
test. Cumulative event-free rates were estimated by Kaplan–Meier
methods with differences between groups compared with the log–rank
test. Additionally, patients were divided into groups on the basis of tertiles
of the baseline SYNTAX score (low  22, intermediate 23–32, and high
33), and groups were compared in a freedom-from-event manner with
a log–rank test. Univariate and multivariate logistic regression models in-
cluding preoperative and intraoperative variables were used to identify
potential predictors of 2-year MACCE. They were expressed as odds ratio
 95% confidence interval. The multivariate models were created by step-
wise selection with an entry and exit criterion for each candidate of
P<.10, beginning with variables with a P value< .10 in the univariate
analysis.RESULTS
Patient Population and Surgical Treatment
Baseline extracardiac and cardiac characteristics, as
well as variables regarding coronary complexity of all132 The Journal of Thoracic and Cardiovascular SurgCABG patients, were depicted in Table 1. Baseline patient
demographics, clinical characteristics, and operative risk
scores of the randomized and registry CABG patients
were comparable, with the exceptions of more carotid ar-
tery disease, less severe angina, higher operative priority,
and lower ejection fraction in the registry population. As
expected, major differences between the groups were
found concerning the complexity of coronary artery dis-
ease indicated by a SYNTAX score of 37.8%  13.3%
for registry and 29.1%  11.4% for randomized patients
(P<.001). In more detail, predictors of being assigned to
the CABG registry were the total number of lesions, the
presence of LM disease, especially in combination with
2-VD and 3-VD, chronic vessel occlusion, bifurcation le-
sions, lesion length greater than 20 mm, and heavy lesion
calcification (Table 1).
CABG was performed by conventional techniques in the
vast majority (80.9%) of patients using predominantly
blood cardioplegic arrest (Table 2). Aminority of 16.6% re-
ceived off-pump bypass surgery. Despite a mean age of
65 years, only 31.5% of the patients received more than 1
arterial graft. Double ITA was used in 22.7% and a radial
artery in 12.8%, leading to complete arterial revasculariza-
tion in only 15.6% of patients. There was a significantly
higher rate of bilateral ITA use and complex graft construc-
tions in the randomized cohort. CABG registry patients
received a significant higher number of distal anastomoses
per patient (registry 3.54  1.0 vs randomized 3.21  0.9;
P< .001), corresponding to a significantly higher rate of
complete revascularization (registry 75.6% vs randomized
63.2%; P<.001). Of note, surgeons’ assessment of vessel
diameter and vessel quality at the anastomotic site and distal
to the anastomosis were significantly unfavorable in regis-
try patients (data not shown).
Early Results
Early mortality andMACCE rates were low. Overall hos-
pital mortality was 1.07% (registry 0.6% vs randomized
1.4%; P ¼ .144) and corresponded to a 30-day postproce-
dure mortality of 0.94% (registry 0.6% vs randomized
1.2%; P¼ .252). Hospital and 30-day postprocedureMAC-
CEs were 4.6% (registry 3.4% vs randomized 5.4%;
P ¼ .067) and 4.4% (registry 3.4% vs randomized 5.2%;
P ¼ .100), respectively.
Discharge medications of the entire CABG population
were as follows: aspirin 88.5%, ß-blocker 78.9%, nitrates
14.0%, angiotensin-converting enzyme inhibitors 44.8%,
thienopyridine 18.4%, statins 71.9%, and amiodarone
12.5%; the regimen was not different between registry
and randomized patients. Aside from ß-blocker medication
and significantly more amiodarone medication (P<.001),
patients who underwent CABG received significantly less
pharmacologic treatment (P < .001 each) at discharge
than did randomized PCI patients.14ery c January 2011
TABLE 1. Baseline characteristics of the CABG study population
Registry RCT Overall
Characteristics (n ¼ 644) (n ¼ 897) (n ¼ 1541)
P
value
Extracardiac variables
Age, y 65.7  9.4 65.0  9.8 65.3  9.6 .140
Female,% 19.3 21.1 20.3 .382
Diabetes,% 29.7 28.5 29.0 .633
COPD,% 7.9 9.3 8.7 .359
Arterial hypertension,% 73.5 77.0 75.5 .114
Hyperlipidemia,% 76.4 77.2 76.9 .739
Peripheral vascular
disease,%
13.8 10.6 11.9 .054
Carotid artery
disease,%
12.3 8.4 10.0 .012
Previous CVA,% 5.5 4.8 5.1 .571
Smoking history,% 64.3 69.1 67.1 .050
Body mass index 28.0  4.6 27.9  4.5 27.9  4.6 .746
Creatinine
>200 mmol/L,%
2.0 1.8 1.9 .738
Abdominal obesity,%* 46.4 45.8 46.1 .841
Cardiac characteristics
Angina assessment
Stable angina,% 62.9 57.2 59.6 .025
Unstable angina,% 21.6 28.0 25.3 .004
Silent ischemia,% 9.0 8.2 8.6 .601
No angina,% 6.5 6.6 6.6 .965
Emergency
indication,%
3.6 3.9 3.8 .738
Urgent indication,% 9.0 3.8 6.0 <.001
Preoperative IABP,% 2.5 1.0 1.6 .023
Previous MI,% 33.5 33.8 33.7 .911
Chronic heart failure,% 5.5 5.3 5.4 .873
Pulmonary
hypertension,%
1.1 1.3 1.2 .660
Ejection fraction
<30%,%
4.5 2.5 3.3 .030
Ejection fraction
30%–50%,%
23.3 17.1 19.7 .003
Coronary complexity
Left dominance,% 5.7 8.7 7.4 .031
Diffuse/small
vessel disease,%
13.6 10.7 11.9 .080
LM disease, any,% 40.3 33.8 36.5 .010
LM disease only,% 1.6 3.1 2.5 .055
LMþ1-VD,% 2.7 5.1 4.1 .017
LMþ2-VD,% 8.4 12.0 10.5 .023
LMþ3-VD,% 27.6 13.5 19.3 <.001
3-VD only,% 59.7 66.2 63.5 .010
Chronic total occlusion,
any,% of patients
56.4 22.2 36.4 <.001
Chronic total occlusion,
% of lesions
15.8 5.6 10.0 <.001
Bifurcation, any,
% of patients
80.8 73.1 76.3 <.001
Bifurcation,%
of lesions
30.2 27.6 28.7 .020
(Continued)
TABLE 1. Continued
Registry RCT Overall
Characteristics (n ¼ 644) (n ¼ 897) (n ¼ 1541)
P
value
Trifurcation, any,
% of patients
16.8 10.6 13.1 <.001
Aorto-ostial lesion 4.2 3.6 3.9 .270
Trifucation,
% of lesions
3.6 2.4 2.9 .004
Lesion length
>20 mm,
% of lesions
31.5 20.3 25.1 <.001
Heavy calcification,
% of lesions
32.7 23.3 27.3 <.001
Severe lesion
tortuosity,
% of lesions
32.5 30.8 31.6 .137
Thrombus formation,
% of lesions
1.0 1.0 1.0 .854
Number of coronary
lesions/patient, n
4.6  1.7 4.4  1.8 4.5  1.8 .005
>5 lesions/patient,% 27.5 25.7 26.5 .433
SYNTAX score 37.8  13.3 29.1  11.4 32.7  12.9<.001
Total Parsonnet score 8.96  7.06 8.43  6.84 8.65  6.94 .145
Additive EuroSCORE 3.89  2.68 3.79  2.69 3.83  2.69 .466
Logistic EuroSCORE,% 4.04  4.44 3.87  4.40 3.94  4.42 .463
RCT, Randomized controlled trial; COPD, chronic obstructive pulmonary disease;
CVA, cerebrovascular accident; IABP, intra-aortic balloon pumping; MI, myocardial
infarction; LM, left main; VD, vessel disease Coronary characteristics were given as
exhibit by core laboratory evaluation P value for comparison of registry versus ran-
domized patients. *Abdominal obesity was defined at waist circumference greater
than 40 inches in men and greater than 35 inches in women.
Mohr et al Acquired Cardiovascular Disease
The Journal of Thoracic and Ca
A
C
DTwo-Year Outcome and Relation to SYNTAX Score
and Presence of LM Disease
One- and 2-year MACCE rates of the entire CABG pop-
ulation were 10.9% and 15.1%, respectively. The incidence
of MACCE and all its components was higher during the
first than during the second year (Figure 1). Comparing reg-
istry and randomized CABG patients showed a significantly
lower MACCE rate at 1 year (registry 8.8% vs randomized
12.4%; P¼ .031) and 2 years of follow-up (registry 13.0%
vs randomized 16.7%; P ¼ .046) for registry patients. This
was exclusively based on differences in the need for repeat
revascularization, which at 1 year (registry 3.0% vs ran-
domized 5.9%;P¼ .009) and 2 years (registry 4.7% vs ran-
domized 8.6%; P ¼ .004) was nearly twice as high for
randomized as for registry patients (Table 3).
With regard to the SYNTAX score, the overall MACCE
rates at 2 years in patients with low (0–22; 15.6%), inter-
mediate (23–32; 14.3%), and high (33; 15.4%) SYN-
TAX scores and all MACCE components were similar
(Figure 2, Table 3). By comparing registry and random-
ized patients, we found a significantly reduced 2-year
MACCE rate for registry patients with low (registry
7.5% vs randomized 17.8%; P ¼ .048) and intermediaterdiovascular Surgery c Volume 141, Number 1 133
TABLE 2. Treatment of CABG patients (registry versus randomized patients)
Registry RCT Overall
(n ¼ 644) (n ¼ 897) (n ¼ 1541) P value
Arterial graft to LAD 94.7 95.6 95.2 .457
BITA use,% 16.1 27.6 22.7 < .001
Radial artery use,% 11.2 14.1 12.8 .100
Gastroepiploic artery use,% 0.0 0.0 0.0
Complete arterial,% 11.2 18.9 15.6 < .001
At least one arterial graft,% 96.7 97.3 97.1 .520
More than one arterial graft,% 26.2 35.3 31.5 < .001
Venous grafts only,% 3.3 2.6 2.9 .432
Grafts per patient, n 3.0  0.9 2.8  0.7 2.9  0.8 < .001
Arterial 1.3  0.7 1.4  0.7 1.4  0.7 .001
Venous 1.7  1.0 1.4  0.8 1.5  1.0 < .001
Distal anastomoses/patient, n 3.5  1.0 3.2  0.9 3.4  0.9 < .001
Graft to LAD territory, any,% 99.1 99.8 99.5 .082
Graft to Cx territory, any,% 93.0 92.5 92.7 .709
Graft to RCA territory, any% 75.8 71.8 73.4 .096
Complete revascularization,% 75.6 63.2 68.1 < .001
Endarterectomy, any,% 1.8 1.2 1.5 .064
Dist. anastomosis from Y-graft,% 3.5 7.7 5.8 < .001
Dist. anastomosis from jump-graft,% 30.4 25.0 27.5 .001
OPCAB,% 18.6 15.0 16.6 .062
Cardioplegia use,% 78.4 82.7 80.9 .041
Blood cardioplegia,% 41.9 50.1 46.6 .002
Crystalloid cardioplegia,% 36.5 32.6 34.3 .116
Procedure time, h 3.6  1.0 3.4  1.1 3.5  1.1 .018
Bypass time, min 93.8  35.0 86.5  35.2 89.5  35.3 < .001
Crossclamp time, min 60.0  26.8 55.0  24.9 57.0  25.8 .001
Aprotinin given,% 32.9 36.7 35.1 .130
Intra-aortic balloon pump,% 4.8 2.9 3.7 .057
Dt consent/revascularization, d 8.1 17.4 13.6 < .001
Postprocedural hospital stay, d 8.2  5.7 9.5  8.0 9.0  7.2 .001
CABG, Coronary artery bypass grafting; RCT, randomized controlled trial; LAD, left anterior descending coronary artery; BITA, bilateral internal thoracic artery; Cx, circumflex;
RCA, right coronary artery; OPCAB, off-pump coronary artery bypass; Dt, time interval randomization/revascularization in days.
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Dscores (registry 9.5% vs randomized 17.0%; P ¼ .042),
but not with high SYNTAX scores (registry 15.2% vs ran-
domized 15.7%; P ¼ .832). In the intermediate SYNTAX
score population, this difference reached significance re-
garding death (P ¼ .037) and repeat revascularization
(P ¼ .037).
The 2-year MACCE rate in LM patients was significantly
higher than in patients with isolated 3-VD (LM 17.0% vs
3-VD 13.2%; P ¼ .042). There was also a trend for higher
mortality (LM 5.9% vs 3-VD 4.1%; P ¼ .082) and symp-
tomatic graft occlusion (LM 3.9% vs 3-VD 2.1%;
P ¼ .063) 2 years postoperatively.
A significant difference was demonstrated between
results in patients treated in the US (261 patients) and out-
side the US (OUS, 1280 patients). Rate of repeat revascular-
ization after 2 years was significantly higher in the US
compared with the OUS cohort (US 11.6% vs OUS
6.0%; P ¼ .002). Overall MACCE rate was significantly
higher (US 19.4% vs OUS 14.3%; P ¼ .04), and all other
components were slightly lower (death: US 4.5%, OUS134 The Journal of Thoracic and Cardiovascular Surg5.1%; P ¼ .738; MI: US 2.1%, OUS 3.5%; P ¼ 0.249;
CVA: US 2.8%, OUS 3.7%; P ¼ .425) in the US.
Univariate and Multivariate Logistic Regression
Model
Twenty-four of 110 analyzed variables had a significant
univariate or multivariate association with 2-year MACCE
rate (Table 4). Widely known extracardiac and cardiac
risk factors (ie, arterial hypertension, EuroSCORE, periph-
eral vascular disease, advanced age, chronic obstructive
pulmonary disease, low ejection fraction, intra-aortic
balloon pumping, and emergency indication) adversely
affected long-term CABG outcomes, whereas medically
treated diabetes was not a significant risk factor
(P ¼ .201). Concerning coronary complexity, neither the
raw SYNTAX score (P ¼ .786) nor most of its elements
(ie, birfurcation/trifurcation; P ¼ .141; lesion length>20
mm; P ¼ .217; diffuse coronary artery disease; P ¼ .224;
number of lesions; P ¼ .375; heavy calcification,
P ¼ .705; aorto-ostial lesion; P ¼ .825; left dominance;ery c January 2011
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FIGURE 1. Overall 2-year MACCE rate and MACCE components of the
entire SYNTAX CABG study population (n¼ 1468), divided by incidence
during the first and second year after allocation. MACCE, Major adverse
cardiac and cerebrovascular event; MI, myocardial infarction; CVA, cere-
brovascular event; RR, repeat revascularization; GO, symptomatic graft
occlusion. Safety end point was defined as combined end point of Death,
MI and CVA.
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DP¼ .837; any chronic total occlusion; P¼ .880; severe tor-
tuosity; P ¼ .916) influenced 2-year MACCE rate. The
presence of coronary thrombus formation and LM disease
(particularly in combination with 2-VD) were significantly
associated with MACCE at 2 years (Table 4).
Concerning the bypass surgical strategy, neither off-
pump coronary bypass (P ¼ .829) nor blood cardioplegia
use (P ¼ .281) significantly influenced 2-year results, butTABLE 3. Incidence of major adverse cardiac and cerebrovascular events
study arm
One year
SYNTAX score
Overall
(n ¼ 1522)
0–22
(n ¼ 343)
23–32
(n ¼ 46
MACCE,% 10.9 12.8 9.7
Randomized 12.4 14.6 12.0
Registry 8.8* 6.0 5.6*
Death,% 3.1 3.1 3.2
Randomized 3.5 3.8 4.2
Registry 2.5 0 1.3
MI,% 3.0 2.8 2.5
Randomized 3.2 3.5 2.5
Registry 2.5 0 2.5
CVA,% 2.2 2.1 2.5
Randomized 2.2 1.9 2.5
Registry 2.2 3.0 2.5
Safety end point,% 7.2 6.7 7.0
Randomized 7.7 7.7 7.7
Registry 6.6 3.0 5.6
Repeat revascularization,% 4.7 6.4 4.1
Randomized 5.9 7.3 5.6
Registry 3.0* 3.0 1.3*
Sympt. graft occlusion,% 2.2 3.6 2.6
Randomized 2.1 4.2 4.2
Registry 2.4 1.5 0
CABG, Coronary artery bypass graft; MACCE, major adverse cardiac and cerebrovascu
randomized versus registry CABG patients.
The Journal of Thoracic and Caprocedural time was associated with worse outcomes. Of
note, the choice of additional arterial grafts (right ITA;
P ¼ .840; radial artery; P ¼ .320) and complex graft con-
structions (jump-graft; P ¼ .500; Y-graft; P ¼ .341) also
did not significantly affect outcome, but there was a trend
toward improved results with an increasing number of distal
arterial anastomoses (P ¼ .311).
In contrast, complete surgical revascularization was
significantly protective against 2-year MACCE (complete
13.0% vs incomplete 18.3%; P¼ .007) (Figure 3). In addi-
tion, the total number of distal anastomoses (P ¼ .01),
conduits (P ¼ .022), and treated vessels (P ¼ .022) had
a beneficial effect on outcomes (Table 4).DISCUSSION
SYNTAX was designed to compare modern surgical and
percutaneous techniques as a primary treatment strategy for
patients with de novo 3-VD or LM disease. Inasmuch as
CABG proved to be superior with regard to the primary
end point of 12-month MACCE,14 the aim of the current
study was to describe the contemporary CABG standard
of care and to identify clinical and coronary risk factors
for adverse surgical outcomewith a special focus on the im-
pact of coronary complexity. Of note, this population is the
largest surgical cohort analyzed in a single controlled mul-
ticenter clinical trial to date.at 1- and 2-year follow-up divided by raw SYNTAX score and CABG
Two years
1)
33
(n ¼ 718) Overall 0–22 23–32 33
10.8 15.1 15.6 14.3 15.4
10.9 16.7 17.8 17.0 15.7
10.6 13.0* 7.5* 9.5* 15.2
3.2 5.0 4.6 4.8 5.2
2.6 5.0 5.4 6.5 3.3
3.5 4.9 1.5 1.9* 6.6
3.4 3.3 2.8 2.8 3.7
4.0 3.5 3.5 2.9 4.0
3.0 3.0 0.0 2.5 3.5
2.2 2.9 3.1 3.0 2.7
2.3 2.9 2.7 2.9 3.0
2.0 3.0 4.5 3.2 2.5
7.7 9.8 8.9 9.4 10.4
7.6 9.9 10.0 10.9 9.0
7.8 9.7 4.5 7.0 11.4
4.2 6.9 7.4 7.1 6.5
5.0 8.6 8.5 9.1 8.4
3.5 4.7* 3.0 3.8* 5.1
2.4 3.1 2.7 2.7 3.3
2.1 2.6 3.0 2.8 2.2
2.7 3.7 1.5 2.6 4.1
lar event; MI, myocardial infarction; CVA, cerebrovascular accident. *P< .05 for
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FIGURE 2. MACCE in CABG patients increased not with high raw SYNTAX scores. Kaplan–Meier curves for 2-year MACCE in CABG divided by raw
SYNTAX score. Patients with low (0–22; 15.6%), intermediate (23–32; 14.3%),and high (33; 15.4%) SYNTAX scores have similar 2-yearMACCE rates.
Numbers in the figure are cumulative event rates  1.5 standard error. MACCE, Major adverse cardiac and cerebrovascular event.
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DSurgical data from 85 sites in Europe and the US revealed
a conventional surgical strategy with cardioplegic arrest and
a single arterial bypass graft in the vast majority of patients.
This is noteworthy because surgical study recommenda-
tions included a liberal use of bilateral ITA, particularly
in patients less than 70 years of age. These recommenda-
tions were based on the knowledge of superior bilateral
ITA long-term results compared with venous bypass graft-TABLE 4. Univariate and multivariate logistic regression for MACCE at
Univariate
Characteristics OR CI
Arterial hypertension 2.15 1.45–3.18
EuroSCORE 1.10 1.05–1.16
Perioperative IABP 2.97 1.65–5.32
Peripheral vascular disease 1.88 1.28–2.76
Complete revascularization 0.66 0.49–0.88
Emergency indication 2.34 1.29–4.26
CCS class 1.41 1.10–1.80
COPD 1.81 1.17–2.80
Age 1.02 1.01–1.03
No. of distal anastomoses 0.81 0.69–0.95
IV inotropes periprocedural 1.42 1.06–1.91
No. of total conduits 0.81 0.67–0.97
No. of vessels treated 0.73 0.55–0.96
Systolic blood pressure 1.01 1.00–1.01
Ejection fraction<30% 1.41 1.02–1.94
Previous TIA 1.78 1.03–3.07
Procedure time 1.14 1.01–1.30
Allocation in the United States 1.45 1.02–2.07
Randomization 1.35 1.00–1.81
LM disease, any 1.33 1.00–1.77
Diastolic blood pressure 1.01 1.00–1.02
Intracoronary thrombus formation 1.84 0.99–3.41
Preoperative ACE inhibitor 1.31 0.98–1.75
LMþ2-VD 1.46 0.97–2.21
Depicted are all variables with P<.1 in univariate analysis in order of probability. MACC
grafting; OR, odds ratio; CI, 95% confidence interval; IABP, intra-aortic balloon pump; CC
IV, intravenous; TIA, transient ischemic attack; LM, left main; ACE, angiotensin-convertin
136 The Journal of Thoracic and Cardiovascular Surging.19 However, a more conservative treatment philosophy
in the majority of centers had to be recognized, which some-
how still reflects the real world of CABG surgery, despite
the fact that all participating sites were encouraged for lib-
eral use of double ITA grafting. Interestingly, the analysis of
the entire SYNTAX CABG population revealed no evi-
dence of a significant advantage of arterial grafting over ve-
nous bypass surgery in the presence of an ITA-to-LAD2 years after allocation including all SYNTAX CABG patients
Multivariate
P OR CI P
<.001 1.86 1.07–3.23 .027
<.001
<.001 2.28 1.12–4.64 .023
.001 1.93 1.18–3.16 .000
.005 0.66 0.51–0.86 .002
.005 2.35 1.13–4.88 .022
.006 1.63 1.05–2.53 .031
.008
.009
.010
.018
.022
.022
.027
.035
.040
.041 1.32 1.11–1.57 .002
.042 1.84 1.14–2.96 .012
.046
.049
.051 1.02 1.00–1.04 .018
.054 2.81 1.26–6.26 .012
.064
.070 1.62 0.95–2.78 .079
E, major adverse cardiac and cerebrovascular event; CABG. coronary artery bypass
S, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease;
g enzyme; VD, vessel disease.
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Danastomosis. Thus, further long-term results are needed to
verify the expected long-term benefit of bilateral ITA and
arterial bypass surgery in the context of a controlled clinical
multicenter trial.
An important conclusion from the current study is that
contemporary CABG results are excellent, with an overall
early mortality rate of about 1%. This very low mortality
rate is even more remarkable given that only a few study ex-
clusion criteria were defined. However, there were a signif-
icant number of cerebrovascular events in the perioperative
and early postoperative period, which may be seen as the
‘‘Achilles heel’’ of modern bypass surgery. All efforts
need to be made to significantly reduce this adverse event
in the future, inasmuch as it might serve as one major reason
to decline CABG as the primary treatment option. We also
need to recognize the significantly decreased administration
of known beneficial discharge medications (ie, angiotensin-
converting enzyme inhibitors, statins, aspirin) in surgical
versus interventional patients. Thus, our intent had to be
that cardiac medication be optimized at discharge and con-
tinued during follow-up in all surgical patients.
The SYNTAX score was initially designed as a compre-
hensive angiographic scoring system to anticipate PCI com-
plexity related to coronary disease and to allow
quantification of coronary artery disease beyond LM and
major 3-VD.15 The SYNTAX score was first retrospectively
validated on 306 patients who underwent PCI for 3-VD dis-
ease in the ARTS II study population and was found to have
great discrimination ability for MACCE 1 year after the
procedure.16 As well, the raw SYNTAX score in random-
ized patients receiving PCI during the SYNTAX trial was
highly predictive of adverse outcomes, indicating that
high SYNTAX scores can serve as a determent for the per-
cutaneous approach.14,20
In contrast, the predictive value of the SYNTAX score
and its components for CABG patients is not clear.
Although the SYNTAX score did not give direction for
1-year MACCE in the randomized CABG cohort of the
SYNTAX study, more recently it was found to be indicative
for MACCE in a surgical population of LM patients.14,18Days since allocation 
Cu
m
ul
at
ive
 M
AC
CE
, %
40
30
20
10
0
Incomplete revascularization
Complete revascularization
0        60      120     180 240     300     360     420    480     540     600     660     720
18.3%
13.0%
p=0.007
FIGURE 3. Two-year freedom from MACCE of SYNTAX coronary ar-
tery bypass patients comparing complete and incomplete revascularization.
MACCE, Major adverse cardiac and cerebrovascular event.
The Journal of Thoracic and CaAdditionally, Capodonno and coworkers17 describe a differ-
ence in 2-year mortality rates in LM surgical patients of
6.2% for SYNTAX scores of 34 or less and 8.5% for scores
above 34. These results, however, need to be assessed
against the background of a mortality difference in PCI
treatment of 8.1% versus 32.7%.17 We herein confirmed
the results of the randomized SYNTAX study population
by finding that 2-year postoperative outcomes were not
influenced by differences in the raw SYNTAX score.
Even though the SYNTAX score is not as important for
surgery as for PCI, the existence of a threshold to define
which patients should be referred for surgery remains un-
clear. The separation into tertiles of less than 22, 22 to 32,
and 32 or more, used in the SYNTAX trial, was not based
on clinical considerations, but on the statistical requirement
for each tertile to include an equal number of patients. This
was also the reason that the thresholds varied (SYNTAX
score level of 19/25, 18/26, and 34) in other studies.16-18
Another limitation of the SYNTAX score is its moderate
interobserver and intraobserver reproducibility of the
score.21,22 Additionally, it remains unknown whether
the raw SYNTAX score or individual score components
are more indicative of adverse outcomes. At least for the
surgical SYNTAX CABG population, we found the
presence of intracoronary thrombus formation and LM
disease rather than the raw SYNTAX score as significant
predictors for 2-year MACCE, whereas important PCI
variables like lesion length, chronic total vessel occlusion,
bifurcation, vessel tortuosity, and calcifications were not
associated with adverse outcomes. However, additional
validation of the SYNTAX score and its components in
other patient populations, clinical scenarios, and for other
end points are required.
We found a significantly worse outcome of randomized
compared with registry patients in groups of low and inter-
mediate SYNTAX scores that was predominantly based on
differences in the rate of repeat revascularization. This find-
ing was unexpected, because randomized patients were
considered to be healthier and to have less complex coro-
nary disease. Indeed, SYNTAX scores were higher in regis-
try patients, but extracardiac and clinical cardiac variables
were evenly balanced between both study populations.
Because the SYNTAX score itself did not significantly
influence 2-year results, other surgical variables had to be
analyzed to explain these notable outcome difference. Dur-
ing univariate analyses, we found that neither off-pump cor-
onary bypass surgery nor the choice of arterial grafts in
addition to ITA-to-LAD anastomosis influenced outcome.
However, there was a significant difference in completeness
of revascularization with an 11% absolute higher rate of
complete revascularization in registry compared with ran-
domized patients (registry 74.7% vs randomized 63.2%;
P<.001). As a surrogate for completeness of revasculariza-
tion, we also found a significantly higher number of graftsrdiovascular Surgery c Volume 141, Number 1 137
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Dand distal anastomoses per patient in the registry, which
were independently protective against 2-year MACCE
rates.
Different definitions of completeness of revasculariza-
tion exist in the literature.23 In the SYNTAX study, the func-
tional classification requiring CABG to all major diseased
and graftable coronary segments presenting significant
flow-compromising lesions was used. This definition has
been advocated in other randomized CABG versus PCI
studies.24 The use of this definition, among others, might
be one reason for the comparably low rate of complete
revascularization found in the SYNTAX trial compared
with other studies in which the traditional definition was
used.14,23
The impact of completeness of revascularization in con-
temporary bypass surgery is still a matter of debate. It was
recently shown that in presence of a left ITA-to-LAD anasto-
mosis, a reasonably incomplete surgical revascularization of
the circumflex or right coronary artery territory did not ad-
versely affect early or long-term survival in patients with
multivessel coronary artery disease.23,24 However, the data
from the present analysis clearly suggest the high impact of
incomplete surgical revascularization on the requirement
for repeat revascularization during the 2-year follow-up,
even if survival might not yet be significantly affected.
In contrast to surgery, there is some evidence that patients
undergoing PCI who receive incomplete revascularization
experience more death with bare metal stents and possibly
also with drug-eluting stents.24,25 Thus, it must be stressed
that the rate of surgical incomplete revascularization is
markedly different from that in PCI of multivessel disease,
and this has to be considered during the primary treatment
decision.25
We also found a surprisingly higher 2-year MACCE rate
in patients treated in the US compared with OUS (US
19.4% vs OUS 14.3%; P ¼ .04). This was exclusively ex-
plained by a notably higher rate of repeat revascularization,
whereas there was a trend of lower incidence of safety end
points in the US CABG population. Reasons for these find-
ings are speculative, and differences might be explained by
a significantly lower number of included patients per center,
a more aggressive use of postoperative coronary angiogra-
phy, and a higher percentage of LM patients.
LIMITATIONS
Although this study provides important information
about contemporary coronary bypass surgery, there are lim-
itations. Two years of follow-up does not adequately reflect
the true long-term effect of arterial grafts over veins regard-
ing patency and the need for reintervention.
Most analyses were applied to the overall 2-yearMACCE
rate, keeping in mind that most differences were found for
the event of repeat revascularization and less for death,
CVA, or MI. A higher rate of repeat revascularization138 The Journal of Thoracic and Cardiovascular Surgdoes not per se indicate a higher incidence of recurrent an-
gina, but it could also only reflect the presence of a vessel
feasible for PCI after initial CABG in a less complex coro-
nary pathologic condition.
The post hoc SYNTAX score subgroup analyses were not
prespecified or statistically powered.
CONCLUSIONS
Surgical patients from the SYNTAX trial form an ideal
population to study the results of current surgical CABG
practice. Outcome data reveal very low early and follow-
up mortality rates, whereas CVA was relatively high. The
raw Syntax score was not predictive of 2-year MACCE,
but patients with LM stenosis were at increased risk. Com-
plete surgical revascularization is a major determinant for
event-free long-term outcome.
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Dr Sheng-Shou Hu (Beijing, China). Congratulations, Dr Ra-
stan, for your excellent presentation.
SYNTAX is a widely known study comparing outcomes of
CABGwith PCI in patients with 3-VD or LM disease. The purpose
of the current study is to describe the current status of CABG basedThe Journal of Thoracic and Caon the SYNTAX CABG cohort and to identify risk factors for ad-
verse outcomes with a special focus on the impact of coronary
complexity quantified by SYNTAX score. As far as we know,
the SYNTAX CABG cohort is the largest one analyzed in a single
controlled multicenter clinical trial right now.
One important conclusion from the current study is the excel-
lent contemporary CABG results. Outcome data demonstrate
very low early and follow-up mortality rates. However, CVAs
were relatively common for CABG patients, which may be said
to be a big limitation of modern CABG when compared with
PCI to treat 3-VD or LM chronic disease. Therefore, we cardiac
surgeons need to spare more effort to reduce CVAs in the future.
The SYNTAX score was initially designed as a comprehensive
angiographic scoring system to anticipate PCI complexity related
to coronary disease, and it can serve as risk stratification and risk
prediction for PCI patients. However, the predictive value of the
SYNTAX score for CABG patients is unclear. A recent study
from another group in your home country, a paper published in
the Annals of Thoracic Surgery last year, found that SYNTAX
score was indicative of 1-year outcomes in CABG patients. How-
ever, your study found that 2-year post-CABG outcomes were not
affected by the SYNTAX score. Therefore, future validation of the
SYNTAX score in other patient populations is required.
I have 3 questions. As I just mentioned, a previous study by Dr
Ozcan Birim found that SYNTAX score was indicative for 1-year
outcomes in CABG patients. How do you explain the difference
between your findings and his?
Dr Rastan.Wementioned this paper from the Rotterdam group
in the paper discussion. This study was a single-center analysis on
patients with LM disease, and data suggested that the SYNTAX
score has an impact on the surgical result in about 150 patients.
As you could read, this was hardly discussed afterward even by
the coauthors. I am, however, sure that the SYNTAX trial data,
having 10-fold more patients available, are more convincing and
clearly demonstrated that the SYNTAX score itself does not affect
the results of CABG.
Dr Hu. Second, we found significantly less completeness of
coronary revascularization and worse outcomes of randomized pa-
tients compared with registry patients. This finding was quite un-
expected and surprising, because registry patients were more
likely to have had LM disease and a higher SYNTAX score,
whereas randomized patients were more likely to have had a bilat-
eral ITA used and more arterial grafts. Why were randomized pa-
tients with lower SYNTAX score associated with less complete
coronary revascularization and adverse outcomes? What is your
comment on that?
Dr Rastan. Thank you very much for mentioning this very im-
portant issue. This is one of the key questions from all our analy-
ses. We knew from the SYNTAX 1-year data, and this was
surprising from the very beginning, that there was a remarkable
difference in the 1-year outcome of randomized CABG patients
compared with the CABG registry. We all speculated about the
reason for this finding, because randomized patients were obvi-
ously healthier and had a less complex coronary anatomy. If any-
thing, the results were expected to be better for randomized
patients, not worse. Identifying the reasons for this unexpected
finding in surgical patients was one of the major reasons that we
made this analysis.rdiovascular Surgery c Volume 141, Number 1 139
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DOf note, we found that the difference between randomized and
registry patients was more remarkable in low SYNTAX scores
than in higher SYNTAX scores. The reasons were not the random-
ization itself but the incompleteness of revascularization and the
higher rate of repeat revascularization. The following question
is, why did randomized patients, or patients with a low SYNTAX
score, receive incomplete revascularization more often? This is re-
ally interesting but difficult to explain. Thus, we have to analyze
this issue further. Maybe it is a matter of the lesion-driven
definition of completeness of revascularization that was used in
this study.
Just looking at the territories of the LAD, circumflex, and right
coronary arteries, we found that there were no significant differ-
ences. Thus, it might be possible that the second vessel of a partic-
ular territory could make the difference regarding a potential target
vessel for the interventionalist to make a PCI postoperatively. The
next step is to go more into detail regarding this issue and, more
important, to correlate these finding to the clinical symptoms of
the patient.
Dr John D. Puskas (Atlanta, Ga). I was particularly fascinated
to see that the SYNTAX score did not affect MACCE at 2 years in
surgical patients but did in PCI patients. As you know, there are
have been several criticisms of database analyses comparing vari-
ous techniques for CABG surgery on the basis that the Society of140 The Journal of Thoracic and Cardiovascular SurgThoracic Surgeons database, for example, does not have detailed
data on coronary anatomy. For instance, there have been those
who criticize comparisons of off-pump versus on-pump surgery
within the Society of Thoracic Surgeons database because coro-
nary complexity cannot be adjusted for; you have now shown
that coronary complexity may in fact not affect MACCE at 2 years
when surgery is performed well. I think that is an important point.
The inability to adjust for coronary anatomic complexity does not
invalidate database comparisons of alternative surgical techniques
for CABG.
Dr Rastan. Thank you for this comment. I completely agree
that it is actually difficult to quantify the complexity of coronary
artery disease. The SYNTAX score is a new tool that we have
available. At the moment, it is speculativewhether or not the SYN-
TAX score is really the only true or best instrument to quantify
complexity of coronary artery disease. However, it is complex to
build and there is a significant interobserver and intraobserver
variability. Maybe we should look more at the predictive value
of individual components of the SYNTAX score, such as chronic
total occlusions or the number of diseased lesions, which also
did not affect the surgical results, but might also be predictive
for PCI results. However, we as surgeons should also try to better
quantify the complexity of artery disease. I agree.
Dr Puskas.Congratulations on a very thought-provoking study.ery c January 2011
